In Q4 2024, HCA Healthcare demonstrated growth in revenue and operating metrics but faced profitability challenges due to hurricane-related disruptions. Strategic initiatives supported admissions growth, though outpatient procedures declined.
馃搳 Income Statement Highlights (vs Q4 2023):
鈻笍Net Income: $1.44B vs $1.61B (-10.51%)
鈻笍Total Revenue: $18.29B vs $17.30B (+5.68%)
鈻笍Adjusted EPS: $6.22 vs $5.90 (+5.42%)
鈻笍Gross Margin: 11.67% vs 12.33%
鈻笍Operating Income: $2.13B vs $2.18B (-2.29%)
鈻笍Adjusted EBITDA: $3.71B vs $3.62B (+2.55%)
鈻笍Same Facility Revenue/Equivalent Admission: $18,185 (+2.9%)
Other Metrics:
鈻笍Same Facility Admissions: +3.0%
鈻笍Emergency Room Visits: +2.4%
鈻笍Inpatient Surgeries: +2.8%; Outpatient Surgeries: -1.3%
馃捈 Balance Sheet Highlights (vs Dec 31, 2023):
鈻笍Total Assets: $59.51B (+0.94%)
鈻笍Cash and Cash Equivalents: $1.93B (+106.68%)
鈻笍Total Liabilities: $43.03B (+0.23%)
鈻笍Equity: $0.56B
Other Key Figures:
鈻笍Debt: $43.03B
鈻笍Share Repurchases: $1.70B in Q4; $764M remains under authorization.
鈻笍Capital Expenditures (excluding acquisitions): $1.29B
馃敭 Future Outlook:
鈻笍2025 Revenue Guidance: $72.80B to $75.80B
鈻笍Net Income: $5.85B to $6.29B
鈻笍Adjusted EBITDA: $14.30B to $15.10B
鈻笍EPS: $24.05 to $25.85
鈻笍Capital Expenditures: $5.0B to $5.2B
馃専 Special Considerations:
鈻笍Hurricanes Helene and Milton impacted operations, contributing to a $200M revenue loss. All facilities have resumed normal operations.
鈻笍HCA鈥檚 board authorized an additional $10B share repurchase program.
鈻笍Q4 2024 dividends declared: $0.72/share.